A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT Save

Date Added
February 28th, 2017
PRO Number
Pro00062003
Researcher
James Thomas
Keywords
Cardiovascular, Cholesterol
Summary

Research study looking for participants with, or at high risk for, cardiovascular disease (CVD). This study is being carried out to see if a new investigational drug called bempedoic acid provides cardiovascular benefits and decreases the risks of future cardiac events when taken by patients who are not able to take a type of medication called statins. The study may require up to 15 visits to the clinic over a period of five years.

Institution
MUSC
Recruitment Contact
Della MacNicholas
843-876-5012
macnichd@musc.edu

A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS) Save

Date Added
June 14th, 2016
PRO Number
Pro00055705
Researcher
James Thomas
Keywords
Cardiovascular, Genetics, Heart
Summary

Research study looking for participants who have recently been hospitalized for a myocardial infarction (heart attack) or ischemia (decreased blood flow to the heart) and are identified as having a genetic variant by a simple blood test. This study is being carried out to see if a new investigational drug called dalcetrapib provides cardiovascular benefits and decreases the risks of future cardiac events when taken by patients with the the genetic variant found in 20% of people.

Institution
MUSC
Recruitment Contact
Della MacNicholas
8438765012
macnichd@musc.edu

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia Save

Date Added
April 22nd, 2014
PRO Number
Pro00033939
Researcher
James Thomas
Keywords
Cardiovascular, Cholesterol, Diabetes, Heart, Stroke
Summary

Research study looking for participants with high triglycerides and either cardiovascular disease or risk factors for cardiovascular disease (e.g.history of heart attack, stroke, stent placement or diabetes type 1 or 2.) This study is being carried out to see if a new investigational drug called Epanova® when added to current treatment for high cholesterol, stroke, and death from heart disease, when compared with placebo (inactive pill having no effect). Medications, all study visits, blood work and study procedures are free of charge.

Institution
MUSC
Recruitment Contact
Della MacNicholas
843-876-5012
macnichd@musc.edu

Change_preferences

-- OR --

Create_login